STEM vs DNA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DNA Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ginkgo Bioworks Holdings, Inc. (DNA) driven by superior Momentum & Technical, Options & Structure while STEM counters with relative strength in Growth & Margin. Fundamentally, STEM trades at N/M Forward P/E with -12.1% operating margin (-4.1% YoY revenue) versus DNA at N/M Forward P/E and -202.5% operating margin (-5.7% YoY). In options structure, STEM sits in BREAKDOWN (39th %ile IV; Dealer Gamma Walls on Pro) against DNA sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | STEM Revenue | DNA Revenue | STEM Op. Margin | DNA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $20M | $50M | -272.6% | -132.1% | DNA |
| FY2020 | $40M | $80M | -136.0% | -178.8% | STEM |
| FY2021 | $130M | $310M | -65.2% | -582.6% | STEM |
| FY2022 | $360M | $480M | -36.1% | -462.4% | STEM |
| FY2023 | $460M | $250M | -38.9% | -343.8% | STEM |
| FY2024 | $140M | $230M | -580.6% | -246.5% | DNA |
| FY2025 | $160M | $170M | -35.6% | -185.3% | STEM |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | STEM | DNA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.1M | $531.5M | Larger Scale | DNA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -4.1% | -5.7% | Higher Growth | STEM |
| Operating Margin (TTM) Profitability | -12.1% | -202.5% | Higher Margin | STEM |
| Net Profit Margin Profitability | -43.6% | -192.0% | Higher Margin | STEM |
| Return on Equity (ROE) Capital Efficiency | -5920.8% | -58.2% | Higher ROE | DNA |
| 52-Week Range Position Momentum | 0% ($1โ$22) | 16% ($5โ$18) | Stronger Trend | DNA |
| Beta / 30D Volatility Risk Regime | 4.60ฮฒ ยท 234% Vol | 3.12ฮฒ ยท 152% Vol | Lower Realized Risk | DNA |
| Unified Institutional Score Composite Signal | 42.4 / 100 (HOLD) | 52.1 / 100 (HOLD) | Higher Composite | DNA |